{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dyskinesias&page=2",
    "query": {
      "condition": "Dyskinesias",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dyskinesias&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:49:22.495Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03563053",
      "title": "Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ataxia Telangiectasia",
        "Genetic Syndrome"
      ],
      "interventions": [
        {
          "name": "EryDex System",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Quince Therapeutics S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2018-06-12",
      "completion_date": "2022-09-02",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03563053"
    },
    {
      "nct_id": "NCT02129348",
      "title": "Treatment of Psychosis and Agitation in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Psychosis",
        "Agitation"
      ],
      "interventions": [
        {
          "name": "Lithium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 77,
      "start_date": "2014-06",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Belmont, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02129348"
    },
    {
      "nct_id": "NCT02074293",
      "title": "ASIS for Botox in Cervical Dystonia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Dystonia Adults ,",
        "Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus."
      ],
      "interventions": [
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox intramuscularly at Week 6",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox intramuscularly at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox intramuscularly at Week 18",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox intramuscularly at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox intramuscularly at Week 30",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox subdermally at Week 6",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox subdermally at Week 18",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Botox subdermally at Week 30",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Botox intramuscularly",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Botox subdermally",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "li nguyen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-01",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 1,
      "location_summary": "Westminster, California",
      "locations": [
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02074293"
    },
    {
      "nct_id": "NCT06997198",
      "title": "Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tardive Dyskinesia",
        "Intellectual Disability",
        "Developmental Disabilities"
      ],
      "interventions": [
        {
          "name": "Deutetrabenazine Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 25,
      "start_date": "2026-05-01",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06997198"
    },
    {
      "nct_id": "NCT05644262",
      "title": "Life's End Benefits of cannaBidiol and tetrahYdrocannabinol",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Agitation",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "T2:C100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-12-18",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 10,
      "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05644262"
    },
    {
      "nct_id": "NCT07137442",
      "title": "Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tics",
        "Functional Tics"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 75,
      "start_date": "2026-05-25",
      "completion_date": "2034-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07137442"
    },
    {
      "nct_id": "NCT00368251",
      "title": "Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unverricht-Lundborg Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "BRV 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "BRV 25 mg",
          "type": "DRUG"
        },
        {
          "name": "BRV 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2006-11",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2023-05-31",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Gainesville, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368251"
    },
    {
      "nct_id": "NCT04857359",
      "title": "Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Dyskinesias"
      ],
      "interventions": [
        {
          "name": "Dipraglurant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Addex Pharma S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-08-06",
      "completion_date": "2022-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Fresno, California • Irvine, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04857359"
    },
    {
      "nct_id": "NCT04231487",
      "title": "Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Essential Tremor",
        "Parkinson Disease",
        "Huntington Disease",
        "Dystonia, Primary",
        "Spinocerebellar Ataxias",
        "Movement Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 210,
      "start_date": "2019-06-27",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04231487"
    },
    {
      "nct_id": "NCT00015457",
      "title": "Amlodipine Plus Botulinum Toxin for Focal Dystonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Dystonia"
      ],
      "interventions": [
        {
          "name": "Amlodipine plus Botulinum toxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2001-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2013-04-01",
      "last_synced_at": "2026-05-22T07:49:22.495Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00015457"
    }
  ]
}